FLICKR, CDC GLOBALWhile a handful of Ebola vaccines are being trialed in humans, researchers are continuing to bring refined options up through the preclinical pipeline. A study published this week (April 8) in Nature provides evidence of the safety and efficacy of two novel vaccine candidates in macaque monkeys. Human safety trials could begin as early as this summer, senior author Thomas Geisbert of the University of Texas Medical Branch in Galveston told The New York Times.
The new vaccine candidates, under development by Profectus BioSciences, are improvements on a Merck vaccine currently being tested in Liberia; they used a more attenuated version of the vesicular stomatitis virus vector. While the vaccine that’s currently in trials can cause fever and joint and muscle pain, these new vaccines appeared to cause no side effects in eight vaccinated monkeys. Importantly, all eight animals survived a challenge with a virus...
“[W]e are trying to find the balance between efficacy and safety,” Geisbert told Time.
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
